Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2017—Qiagen has joined Cancer-ID, a public-private consortium of 36 partners from 13 countries that aims to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.
July 2017—To define the current state of reagents and serological assay technology used to measure total human immunoglobulin E and IgE antibodies of defined allergen specificities in human blood, the Clinical and Laboratory Standards Institute published a revised document that focuses on IgE assay design and calibration, validation methods, quality assurance of assay reagents, quality control strategies, and clinical applications.
July 2017—Streck has signed distribution agreements with Anopoli Biomedical Systems, an Austrian distributor of life sciences, molecular diagnostics, and microarray products, and with Ngaio Diagnostics,
July 2017—Myriad Genetics has launched the EndoPredict test in the U.S. for patients with ER+ HER2- early stage breast cancer. EndoPredict is a second-generation test for assessing the 10-year risk of disease recurrence following surgery and for determining which patients can safely forgo adjuvant chemotherapy.
July 2017—Randox Quality Control launched a centralized platform for the management of daily quality control activities
July 2017—Becton Dickinson received 510(k) clearance from the FDA for its BD FACSVia, a flow cytometer system with a leucocount reagent assay used in residual white blood cell enumeration.
July 2017—Siemens Healthineers announced a strategic alliance with Relaymed to bring customers secure, cloud-based connectivity for Siemens DCA Vantage analyzer and Clinitek Status point-of-care instruments.
July 2017—Hemo Bioscience announced its MQC-CAT—a ready-to-use quality control product for manual column agglutination technology blood bank testing methods—has received FDA 510(k) clearance.
July 2017—Helomics and MDNA Life Sciences announced the commercial launch of MDNA’s liquid biopsy Prostate Mitomic Test in select U.S. markets. The proprietary test, which utilizes MDNA’s Mitomic Technology platform, uses the unique biological characteristics of mitochondrial DNA and is available in the clinical laboratories of Helomics.
July 2017—ClearLight Diagnostics has signed a collaboration agreement with the Indiana University Melvin and Bren Simon Cancer Center to study the tumor microenvironment in patients with breast cancer.
